Abstract
Minocycline is a new tetracycline family antibiotic which has a broad antibacterial spectrum, and is more potent than other tetracyclines. Minocycline was tested with the following results:
1.In vitro antibacterial activity: The minimum inhibitory concentration of minocycline was estimated by an agar-plate dilution method. Minocycline inhibited the growth of 60 strains of coagulase-positive Staphylococcus aureus at <0.19-50mcg/ml. Minocycline sensitivity is higher than other tetracyclines.
2. Serum level: A peak serum level of 2.3mcg/ml was reached 2 hours after oral administration of 100mg minocycline dry-syrup in healthy children, followed by a gradual decrease in the level. An effective level of 0.9mcg/ml was still demonstrable after 24 hours.
3. Concentration in tissues: Two hours after the oral administration of 100mg minocycline drysyrup, 1.5mcg/g was found in a human platine tonsilla specimen, and 0.9mcg/g in a human maxillary sinusitis specimen, while 2.2 mcg/ml in serum.
4. Clinical effect: By the oral administration of 4mg/kg minocyclne dry-syrup, 27 of 30 cases (90%) of infections in otorhinolaryngological field showed good results. No side effect was observed.
